Arbutus Biopharma Shares Jump After Achieving First Milestone Under COVID-19 Pact


Arbutus Biopharma Corporation ABUS has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for treating COVID-19 and potential future coronavirus outbreaks. 

  • In April 2021, Arbutus, X-Chem Inc, and Proteros biostructures GmbH entered a discovery research and license agreement of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease. 
  • Upon achieving this milestone, Arbutus has obtained a worldwide exclusive license to the identified molecules. 
  • The parties will continue to accelerate the development of pan-coronavirus agents to treat COVID-19 and potential future coronavirus outbreaks.
  • In exchange for that license, Arbutus shall make a milestone payment to X-Chem and Proteros.
  • Related Link: Arbutus' Hepatitis B Candidate Shows Encouraging Antiviral Activity
  • Price Action: ABUS shares are up 7.82% at $4 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!